Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.14% | -62.31% | -41.33% | -29.12% | -44.21% |
| Total Depreciation and Amortization | 101.20% | 72.71% | 49.55% | 54.99% | 103.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.59% | 98.28% | 55.82% | 51.43% | 50.95% |
| Change in Net Operating Assets | 163.87% | 92.82% | 30.22% | -32.34% | -38.76% |
| Cash from Operations | -15.54% | -22.75% | -24.81% | -22.97% | -38.09% |
| Capital Expenditure | -1.83% | 33.94% | -14.55% | 19.05% | 58.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 390,387.32% | 14,927.33% | 14,927.33% | -103.71% | -103.71% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.77% | -9,162.50% | -2,763.25% | -1,537.77% | -104.83% |
| Cash from Investing | 1,986.00% | 2,348.00% | 2,642.62% | -13.78% | -136.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,006.36% | -741.28% | -479.63% | -3,092.63% | -719.15% |
| Issuance of Common Stock | -57.11% | 120.58% | 118.99% | 82.36% | 165.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.83% | 117.44% | 117.02% | 80.98% | 164.93% |
| Foreign Exchange rate Adjustments | 3,459.45% | 5,775.86% | -1,911.70% | 178.19% | -156.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.50% | 215.20% | 227.85% | 157.07% | 239.43% |